NRIX
Nurix Therapeutics Inc
3월 13일 4:00 PM ET (한국 3/14 05:00)
$15.04
-0.57 ▼ -3.65%
🌙 3월 13일 4:45 PM ET (한국 3/14 05:45)
$15.14
+0.10 ▲ +0.66%
| Index | RUT | P/E | - | EPS (ttm) | -3.04 | Insider Own | 5.89% | Shs Outstand | 0.10B | Perf Week | -0.4% |
| Market Cap | 1.55B | Forward P/E | - | EPS next Y | 4.23% | Insider Trans | -1.59% | Shs Float | 0.10B | Perf Month | -6.64% |
| Enterprise Value | 1.01B | PEG | - | EPS next Q | -0.76 | Inst Own | 105.07% | Short Float | 16.5% | Perf Quarter | -23.3% |
| Income | -0.26B | P/S | 18.42 | EPS this Y | -2.46% | Inst Trans | 30.28% | Short Ratio | 13.58 | Perf Half Y | 63.48% |
| Sales | 0.08B | P/B | 2.84 | EPS next 5Y | 6.26% | ROA | -38.38% | Short Interest | 15.97M | Perf YTD | -20.72% |
| Book/sh | 5.29 | P/C | 2.61 | EPS past 3/5Y | 6.31% -2.04% | ROE | -49.63% | 52W High | -33.16% ($22.50) | Perf Year | 14.03% |
| Cash/sh | 5.77 | P/FCF | - | Sales past 3/5Y | 29.55% 36.35% | ROIC | -44.7% | 52W Low | 83.86% ($8.18) | Perf 3Y | 63.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.27% | Gross Margin | 77.55% | Volatility(W/M) | 6.33% 5.49% | Perf 5Y | -65.94% |
| Dividend TTM | - | EV/Sales | 12.02 | Sales Y/Y TTM | 53.95% | Oper. Margin | -340.16% | ATR (14) | 0.93 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.02 | EPS Q/Q | -10.16% | Profit Margin | -314.9% | RSI (14) | 39.43 | Recom | 1.06 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.02 | Sales Q/Q | 2.21% | SMA20 | -4.13% ($15.69) | Beta | 2 | Target Price | $30 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 1000000 | SMA50 | -11.54% ($17) | Rel Volume | 0.64 | Prev Close | $15.61 |
| Employees | 317 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | 5.86% 1.33% | SMA200 | 11.95% ($13.43) | Avg Volume(3M) | 1.18M | Price | $15.04 |
| IPO | 2020/7/24 | Option/Short | Yes/Yes | Trades | 10964 | Volume | 757,328 | Change | -3.65% |
뉴스 로딩 중...